SCHEMBL7224031

SCHEMBL7224031

Cc1ccccc1NC(=O)Nc1cc(C(=O)Nc2cccc3cc(S(=O)(=O)O)ccc23)cc(C(=O)Nc2cccc3cc(S(=O)(=O)O)ccc23)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TIMP3 P35625 4/20 0.57
CASP6 P55212 1/20 0.57
FGF1 P05230 1/20 0.56
DDX3X O00571 2/20 0.48
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
CYP1A2 P05177 3/20 0.48
RECQL P46063 3/20 0.48
HSD17B10 Q99714 3/20 0.48
TDP1 Q9NUW8 3/20 0.48
HPSE Q9Y251 2/20 0.48
USP2 O75604 2/20 0.48
MAPT P10636 2/20 0.48
PKM P14618 2/20 0.48
BRCA1 P38398 2/20 0.48
P2RX1 P51575 2/20 0.48
ENPP3 O14638 1/20 0.48
ENTPD3 O75355 1/20 0.48
NR1I2 O75469 1/20 0.48
PRKD3 O94806 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7223972 0.89 FGF1 (0.63) TIMP3CASP6FGF1MEN1KMT2A
SCHEMBL7225097 0.89 TIMP3 (0.58) TIMP3CASP6FGF1MEN1KMT2A
SCHEMBL7234616 0.89 FGF1 (0.62) TIMP3CASP6FGF1MEN1KMT2A
SCHEMBL7233875 0.88 CASP6 (0.57) TIMP3CASP6FGF1MEN1KMT2A
SCHEMBL7224576 0.88 TIMP3 (0.57) TIMP3CASP6FGF1MEN1KMT2A
SCHEMBL7232738 0.87 HPGD (0.55) TIMP3CASP6FGF1MEN1KMT2A
SCHEMBL7233377 0.85 CASP6 (0.60) TIMP3CASP6FGF1MEN1KMT2A
SCHEMBL7231212 0.85 CASP6 (0.75) TIMP3CASP6FGF1MEN1KMT2A
SCHEMBL7226724 0.84 FGF1 (0.62) TIMP3CASP6FGF1MEN1KMT2A
SCHEMBL7222503 0.84 TIMP3 (0.58) TIMP3CASP6FGF1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6653321-B1 Stimulating kinase activity of insulin receptor; type II diabetes; hyperglycemia TELIK, INC. 2003-11-25 US disclosed